论文部分内容阅读
目的:分析代谢综合征和肾癌恶性程度的相关性。方法:收集2013年1月~2016年1月期间我院收治的668例肾癌手术治疗患者的一般资料,根据有无代谢综合征分为单纯性肾癌组和肾癌合并代谢综合征组。统计分析两组间肾癌Fuhrman分级的差异。结果:本研究共纳入668例肾细胞癌患者,平均年龄为(62.7±9.0)岁,男性451例,女性217例,病理类型为透明细胞癌588例,非透明细胞癌80例。单纯肾癌组包含552例患者,平均年龄(62.5±9.0)岁,男性375例,女性177例,病理类型为透明细胞癌486例,非透明细胞癌66例。Fuhrman分级Ⅰ、Ⅱ级399例,Fuhrman分级Ⅲ、Ⅳ级153例;肾癌合并代谢综合征组包括116例患者,平均年龄(63.7±8.9)岁,男性76例,女性40例,病理类型为透明细胞癌102例,非透明细胞癌14例。Fuhrman分级Ⅰ、Ⅱ级71例,Fuhrman分级Ⅲ、Ⅳ级45例。肾癌合并代谢综合征组患者的Fuhrman分级明显高于单纯肾癌组,且存在统计学意义(P=0.018)。结论:肾癌伴有代谢综合征预示了更高的恶性程度。
Objective: To analyze the correlation between metabolic syndrome and malignant degree of renal cell carcinoma. Methods: The data of 668 patients with renal cell carcinoma treated in our hospital from January 2013 to January 2016 were collected. According to the presence or absence of metabolic syndrome, the patients were divided into simple renal cell carcinoma group and renal cell carcinoma combined metabolic syndrome group. Differences in Fuhrman classification of renal cell carcinoma between the two groups were statistically analyzed. Results: A total of 668 patients with renal cell carcinoma were enrolled in this study. The average age was (62.7 ± 9.0) years. There were 451 males and 217 females. The pathological types were clear cell carcinoma 588 and non-clear cell carcinoma 80. The simple renal cell carcinoma group comprised 552 patients, with an average age of 62.5 ± 9.0 years, 375 males and 177 females, with 486 clear cell carcinomas and 66 non-clear cell carcinomas. Fuhrman gradeⅠ, Ⅱ grade 399 cases, Fuhrman gradeⅢ, Ⅳ grade 153 cases; renal cell carcinoma combined metabolic syndrome group, including 116 patients, the average age was (63.7 ± 8.9) years, 76 males and 40 females, pathological type was 102 cases of clear cell carcinoma, non-clear cell carcinoma in 14 cases. Fuhrman grade Ⅰ, Ⅱ grade 71 cases, Fuhrman grade Ⅲ, Ⅳ grade 45 cases. The Fuhrman grade in patients with renal cell carcinoma and metabolic syndrome was significantly higher than that in simple renal cell carcinoma (P = 0.018). Conclusion: Renal cancer associated with metabolic syndrome predicts a higher degree of malignancy.